Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections
Urogenital Tract Infection · 2015
DOI: 10.14777/uti.2015.10.2.84 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urogenital Tract Infection, 2015. Verfasst von Yong Kwan Lim und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Extended-spectrum beta-lactamases (ESBLs) are enzymes that confer increased resistance to commonly used antibiotics. The prevalence rates of ESBL producing bacteria are increasing, and the associated increase in morbidity and mortality is becoming a public health concern. ESBL producers are emerging as an important cause of urinary tract infection (UTI) and empirical therapy should therefore be carefully selected for patients with UTI. Fosfomycin or nitrofurantoin would be an appropriate choice for empirical therapy of uncomplicated UTI. Ertapenem or cefepime might be recommended for initial empirical therapy patients suspected of having complicated UTI.
Zitieren
APA
Lim, Y. K., Lee, M., & Kim, T. (2015). Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections. Urogenital Tract Infection. https://doi.org/10.14777/uti.2015.10.2.84
Vancouver
Lim YK, Lee M, Kim T. Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections. Urogenital Tract Infection. 2015. doi:10.14777/uti.2015.10.2.84
BibTeX
@article{Lim2015,
author = {Lim, Yong Kwan and Lee, Mi-Kyung and Kim, Tae-Hyoung},
title = {Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections},
journal = {Urogenital Tract Infection},
year = {2015},
doi = {10.14777/uti.2015.10.2.84}
}
EUVIMED